Enterprise Value

222.1M

Cash

310.5M

Avg Qtr Burn

-29.42M

Short % of Float

13.74%

Insider Ownership

32.60%

Institutional Own.

64.31%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma

Approved

Update

Camidanlumab Tesirine (CD25) Details
Solid tumor/s, Hodgkin Lymphoma, Cancer

BLA

Submission

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Blood cancer, Cancer, Diffuse large B cell lymphoma

Phase 2

Data readout

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Non-Hodgkin lymphoma, Blood cancer, Cancer

Phase 1b

Interim update

ADCT-601 (AXL) Details
Solid tumor/s, Cancer

Phase 1b

Interim update

ADCT-602 (CD22) Details
Acute lymphoblastic leukemia

Phase 1a

Data readout